We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Current and Emerging Treatments for Urothelial Carcinoma: A Focus on Enfortumab Vedotin.
- Authors
Shafique, Muhammad Ashir; Haseeb, Abdul; Siddiq, Mohammad Arham; Mussarat, Abdullah; Rangwala, Hussain Sohail; Mustafa, Muhammad Saqlain
- Abstract
Urothelial carcinoma is a common malignancy that affects the urinary system, with bladder cancer being the most prevalent form. Although the management of early-stage disease has seen significant improvements, the treatment of locally advanced and metastatic urothelial carcinoma remains challenging. Over the past decade, there has been an explosion in the number of therapies available for the treatment of advanced disease, with immune checkpoint inhibitors and antibody-drug conjugates leading the way. Enfortumab vedotin is an antibody-drug conjugate that targets Nectin-4, a protein that is overexpressed in urothelial carcinoma cells. In clinical trials, it has shown promising outcomes for the treatment of advanced urothelial carcinoma that has progressed after chemotherapy or immunotherapy. The US Food and Drug Administration has granted expedited approval for enfortumab vedotin in the treatment of advanced urothelial carcinoma. This review provides an overview of the current and emerging treatments for urothelial carcinoma, with a particular focus on enfortumab vedotin. We discuss the mechanisms of action, clinical efficacy, safety, and ongoing research of enfortumab vedotin, along with the current landscape of other approved therapies and promising agents in development. The aim of this review is to provide a comprehensive and up-to-date summary of the available treatment options for urothelial carcinoma, including their limitations and future prospects.
- Subjects
TRANSITIONAL cell carcinoma; IMMUNE checkpoint inhibitors; ANTIBODY-drug conjugates; BLADDER cancer; DISEASE management; THERAPEUTICS
- Publication
Cancer Management & Research, 2023, Vol 15, p699
- ISSN
1179-1322
- Publication type
Article
- DOI
10.2147/CMAR.S418009